These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 8457260

  • 1. Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100.
    Schmidt EB, Illingworth DR, Bacon S, Mahley RW, Weisgraber KH.
    Atherosclerosis; 1993 Jan 25; 98(2):213-7. PubMed ID: 8457260
    [Abstract] [Full Text] [Related]

  • 2. Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100.
    Schmidt EB, Illingworth DR, Bacon S, Russell SJ, Thatcher SR, Mahley RW, Weisgraber KH.
    Metabolism; 1993 Feb 25; 42(2):137-9. PubMed ID: 8474308
    [Abstract] [Full Text] [Related]

  • 3. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia.
    Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ.
    Arterioscler Thromb Vasc Biol; 1997 May 25; 17(5):826-33. PubMed ID: 9157944
    [Abstract] [Full Text] [Related]

  • 4. Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100.
    Illingworth DR, Vakar F, Mahley RW, Weisgraber KH.
    Lancet; 1992 Mar 07; 339(8793):598-600. PubMed ID: 1347103
    [Abstract] [Full Text] [Related]

  • 5. Familial defective apolipoprotein B-100: a lesson from homozygous and heterozygous patients.
    Ceska R, Vrablík M, Horínek A.
    Physiol Res; 2000 Mar 07; 49 Suppl 1():S125-30. PubMed ID: 10984082
    [Abstract] [Full Text] [Related]

  • 6. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia.
    Gaffney D, Forster L, Caslake MJ, Bedford D, Stewart JP, Stewart G, Wieringa G, Dominiczak M, Miller JP, Packard CJ.
    Atherosclerosis; 2002 May 07; 162(1):33-43. PubMed ID: 11947895
    [Abstract] [Full Text] [Related]

  • 7. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia.
    Myant NB.
    Atherosclerosis; 1993 Dec 07; 104(1-2):1-18. PubMed ID: 8141833
    [Abstract] [Full Text] [Related]

  • 8. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
    Raal FJ, Pilcher G, Rubinsztein DC, Lingenhel A, Utermann G.
    Atherosclerosis; 1997 Feb 28; 129(1):97-102. PubMed ID: 9069523
    [Abstract] [Full Text] [Related]

  • 9. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia.
    Miserez AR, Keller U.
    Arterioscler Thromb Vasc Biol; 1995 Oct 28; 15(10):1719-29. PubMed ID: 7583549
    [Abstract] [Full Text] [Related]

  • 10. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC.
    Metabolism; 1990 Mar 28; 39(3):269-73. PubMed ID: 2106607
    [Abstract] [Full Text] [Related]

  • 11. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR, Bacon S.
    Arteriosclerosis; 1989 Mar 28; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [Abstract] [Full Text] [Related]

  • 12. Identification of a heterozygous compound individual with familial hypercholesterolemia and familial defective apolipoprotein B-100.
    Rauh G, Schuster H, Fischer J, Keller C, Wolfram G, Zöllner N.
    Klin Wochenschr; 1991 May 03; 69(7):320-4. PubMed ID: 2067318
    [Abstract] [Full Text] [Related]

  • 13. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100.
    Rubinsztein DC, Raal FJ, Seftel HC, Pilcher G, Coetzee GA, van der Westhuyzen DR.
    Arterioscler Thromb; 1993 Jul 03; 13(7):1076-81. PubMed ID: 8318509
    [Abstract] [Full Text] [Related]

  • 14. Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred.
    Davignon J, Dufour R, Roy M, Bétard C, Ma Y, Ouellette S, Boulet L, Lussier-Cacan S.
    Eur J Epidemiol; 1992 May 03; 8 Suppl 1():10-7. PubMed ID: 1505645
    [Abstract] [Full Text] [Related]

  • 15. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia.
    Groot PH, Dijkhuis-Stoffelsma R, Grose WF, Ambagtsheer JJ, Fernandes J.
    Acta Paediatr Scand; 1983 Jan 03; 72(1):81-5. PubMed ID: 6407278
    [Abstract] [Full Text] [Related]

  • 16. Familial defective apolipoprotein B-100 (R3500Q) in Northern Ireland.
    McClean E, Graham CA, Ward AJ, Young IS, Martin S, Nicholls DP.
    Br J Biomed Sci; 1999 Jan 03; 56(4):258-62. PubMed ID: 10795369
    [Abstract] [Full Text] [Related]

  • 17. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L, Nowicka G, Szostak WB, Naruszewicz M.
    Atherosclerosis; 1987 Feb 03; 63(2-3):203-9. PubMed ID: 3827981
    [Abstract] [Full Text] [Related]

  • 18. Familial defective apolipoprotein B100: clinical characteristics of 54 cases.
    Rauh G, Keller C, Kormann B, Spengel F, Schuster H, Wolfram G, Zöllner N.
    Atherosclerosis; 1992 Feb 03; 92(2-3):233-41. PubMed ID: 1632851
    [Abstract] [Full Text] [Related]

  • 19. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
    Wierzbicki AS, Lumb PJ, Cheung J, Crook MA.
    QJM; 1997 Oct 03; 90(10):631-4. PubMed ID: 9415344
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.